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A Role for Ifit2 in Restricting West Nile Virus Infection in the Brain
Hyelim Cho,a Bimmi Shrestha,b Ganes C. Sen,d Michael S. Diamonda,b,c
Departments of Molecular Microbiology,a Medicine,b and Pathology and Immunology,c Washington University School of Medicine, St. Louis, Missouri, USA; Department
of Molecular Genetics, Lerner Research Institute, Cleveland Clinic, Cleveland, Ohio, USAd
Previous studies have demonstrated that type I interferon (IFN-I) restrictsWest Nile virus (WNV) replication and pathogenesis
in peripheral and central nervous system (CNS) tissues. However, the in vivo role of specific antiviral genes that are induced by
IFN-I againstWNV infection remains less well characterized. Here, using Ifit2/mice, we defined the antiviral function of the
interferon-stimulated gene (ISG) Ifit2 in limiting infection and disease in vivo by a virulent North American strain of WNV.
Compared to congenic wild-type controls, Ifit2/mice showed enhancedWNV infection in a tissue-restricted manner, with
preferential replication in the CNS of animals lacking Ifit2. Virological analysis of cultured macrophages, dendritic cells, fibro-
blasts, cerebellar granule cell neurons, and cortical neurons revealed cell type-specific antiviral functions of Ifit2 againstWNV.
In comparison, small effects of Ifit2 were observed on the induction or magnitude of innate or adaptive immune responses. Our
results suggest that Ifit2 restrictsWNV infection and pathogenesis in different tissues in a cell type-specific manner.
West Nile virus (WNV) is a mosquito-transmitted, neu-rotropic, positive-stranded RNA virus in the Flaviviridae
family, which includes other pathogens of global health concern,
such as dengue, yellow fever, and Japanese encephalitis viruses.
WNV is maintained in an enzootic cycle between Culex species
mosquitoes and several avian hosts but can cause disease in verte-
brate animals, including horses and humans (1). Before 1999, the
distribution of WNV was localized largely to Africa, central and
southern Asia, the Middle East, southern Europe, and Oceania
(2). Since its entry into North America in New York City in 1999,
WNV has spread across the continental United States into Can-
ada, Mexico, and parts of South America, likely due to bird mi-
gration and the presence of competent mosquito hosts (3, 4).
While human transmission usually occurs through mosquito in-
oculation, other routes (blood transfusion, organ transplantation,
and intrauterine transmission) have been reported (1). Although
the majority (50 to 70%) of human infections are asymptom-
atic, WNV infection in the elderly or immunocompromised can
cause severe neuroinvasive disease, includingmeningitis, enceph-
alitis, and acute flaccid paralysis (5–7). In the United States alone
between 1999 and 2012, 36,000 cases and 1,500 deaths have
been confirmed (http://www.cdc.gov/ncidod/dvbid/westnile
/surv&control.htm). Despite this, no approved vaccines or thera-
peutics are available to treat or prevent human WNV infection.
RNA intermediates of viral replication are recognized by cyto-
solic and endosomal pattern recognition receptors (PRR), such as
RIG-I-like receptors (RLR) or Toll-like receptors (TLR), which
signal specific transfection factors (e.g., Irf3 or Irf7) to induce type
I interferon (IFN-I) expression and secretion. Autocrine and
paracrine binding of IFN-I to its receptor (Ifnar) results in a sig-
naling cascade that includes Stat1, Stat2, and Irf9 and results in the
induction of many interferon-stimulated genes (ISGs), some of
which inhibit virus infections. Although IFN-I responses control
the cell and tissue tropism of several families of RNA and DNA
viruses, the specific molecules that mediate this remain poorly
characterized.While earlier studies definedMx1, Pkr, andRNaseL
as broad-spectrum antiviral ISGs against several families of RNA
viruses, more recent investigations have identified other ISGs
(e.g., Ifit1, Ifitm genes, Bst2, Apobec3g, and Adar) that restrict in-
fection of a more limited range of viruses (8–10). Several individ-
ual ISGs have been suggested to have antiviral activity against
WNV. C6orf150, Hpse, Nampt, Phf15, Ifitm2, Ifitm3, and Isg20
inhibit WNV infection in vitro (10, 11), and viperin (Rsad2), Pkr,
and RNaseL restrict WNV pathogenesis in vivo and in vitro in a
tissue- and cell type-specific manner (8, 12).
Ifit2 (also known as ISG54) is a member of the IFN-induced
proteins with tetratricopeptide repeats (IFIT) family. IFIT pro-
teins contain multiple tetratricopeptide repeats, which are do-
mains implicated in the regulation of cell cycle, transcription,
protein transport, and protein folding processes (13). Initial ex-
periments indicated that Ifit2 could restrict infection of several
viruses by binding to and inhibiting subunits of eIF3, a key protein
involved in initiation of host translation (14). More recent struc-
tural and functional studies suggest that IFIT familymembers also
inhibit infection of cytoplasmic RNA andDNA viruses by directly
binding nonself RNA, including moieties displaying 5=-ppp RNA
(15, 16) and possibly 5= cap 0 structures (7mGpppN) lacking 2=-O
methylation (17, 18). Ifit2, in particular, has been demonstrated to
have antiviral activity in cell culture against WNV (19). While in
vivo studies have established an antiviral effect of Ifit2 against ve-
sicular stomatitis virus (VSV) infection (20), analogous experi-
ments have not been conductedwithWNVor any other flavivirus.
Beyond its antiviral function, Ifit2 has been implicated in the
regulation of host cell immune responses. One study showed that
human IFIT1 and IFIT2 bind to and inhibit MITA (also known as
STING), which functions as a mitochondrial adaptor protein that
recruits TANK-binding kinase 1 (TBK1) and IRF-3 to a complex
with MAVS (also known as IPS-1, CARDIF, and VISA), resulting
in the downstream induction of IFN- expression in response to
viral RNA or DNA (21). However, these data conflict with the
results from mouse fibroblasts, macrophages, and dendritic cells
in which silencing of IFIT2 expression did not alter IFN-I re-
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sponses (22). Finally, expression of human IFIT2 also has been
suggested to promote apoptosis via amitochondrial pathway (23).
Here, we examined in detail the function of Ifit2 in vivo against
WNV infection and pathogenesis using Ifit2/ mice. Our data
indicate that Ifit2 restricts WNV infection in a cell- and tissue-
specific manner yet had small effects on the induction and mag-
nitude of the innate and adaptive antiviral immune responses.
Thus, Ifit2 is a key antiviral effector molecule that functions
downstream of host pathogen recognition signaling to inhibit in-
fection by WNV and possibly other viruses.
MATERIALS AND METHODS
Virus propagation and titration. The WNV strain (3000.0259) was iso-
lated in New York in 2000 and passaged once in C6/36 Aedes albopictus
cells to generate an insect cell- derived stock virus as described previously
(24). Mammalian cell-derived WNV was generated from an infectious
cDNA clone of theNewYork 1999 strain, propagated once in C6/36Aedes
albopictus cells, and passaged a second time inVero cells (25).WNV-NS5-
E218A was propagated in BHK-21-15 cells as described previously (26).
BHK-21-15 and Vero cells were used for titration of virus in tissue and
cells by plaque or focus-forming assay as described previously (27, 28).
Levels of virus in serum and lymph nodes were determined by quantita-
tive reverse transcription (RT)-PCR using WNV-specific primers and
probe as described previously (8).
Mouse experiments and tissue preparation.C57BL/6 wild-typemice
were obtained commercially (Jackson Laboratory), and the generation of
congenic Ifit2/mice was described previously (20). Mice were bred in
the animal facility of Washington University School of Medicine, and
experiments were performed according to the guidelines and with ap-
proval of the Washington University Animal Studies Committee. For in-
fection, 8- to 10-week-old age-matched mice were used. Mice were in-
fected subcutaneously in the footpad (102 PFU in 50 l) or intracranially
(101 PFU in 10 l) with virus diluted in Hanks balanced salt solution
(HBSS) supplemented with 1% heat-inactivated fetal bovine serum
(FBS). On specific days after infection, mice were perfused extensively
with phosphate-buffered saline (PBS), tissues were harvested and
weighed, and virus titers were determined by plaque assay on BHK-21-15
cells (27). For survival studies, 8-week-old mice were infected via footpad
inoculation and monitored for 21 days.
IFN bioassay. Levels of biologically active IFN-I in serum of mice
infected with WNV were determined using an encephalomyocarditis vi-
rus L929 cell cytopathic effect bioassay as described previously (28, 29).
Cytokine analysis. Mice were infected subcutaneously with 102 PFU
of WNV in the footpad, and serum was collected at 2 days after infection.
Cytokine levels in serum were measured using a Bio-Plex Pro 8-plex cus-
tom cytokine kit (Bio-Rad) and Bio-Plex 200 (Bio-Rad).
Measurement of WNV-specific antibodies. The levels of WNV-spe-
cific IgM and IgG were measured using an enzyme-linked immunosor-
bent assay (ELISA) with purified WNV E protein as described previously
(30). The titer of neutralizing antibody in serum was quantitated by a
focus reduction neutralization assay in Vero cells as described previously
(31).
Analysis of splenic CD4 and CD8 T cells. Splenocytes were har-
vested from wild-type or Ifit2/ mice on day 8 after WNV infection.
Intracellular IFN- or tumor necrosis factor alpha (TNF-) staining of
CD8 T cells was performed after ex vivo restimulation with an immuno-
dominant Db-restricted NS4B peptide as described previously (32). Sam-
ples were processed, stained with antibodies against IFN- and TNF-
(BD Pharmingen), and analyzed using an LSR II flow cytometer (Becton,
Dickinson) and FlowJo software (Treestar).
CNS leukocyte isolation and phenotyping. Brains were harvested
fromwild-type and Ifit2/mice on day 8 afterWNV infection, and CNS
leukocytes were isolated after Percoll gradient centrifugation as described
previously (33). Cells were stained forCD3,CD4,CD8,CD45, andCD11b
with directly conjugated antibodies (BDPharmingen). Intracellular stain-
ing for IFN- and TNF- was performed after NS4B peptide restimula-
tion as described before (32).
Primary cell isolation and infection.Primarymacrophages, dendritic
cells, embryonic fibroblasts, cortical neurons, and cerebellar granule cell
neurons were prepared from embryonic, neonatal, and adult wild-type
and Ifit2/ mice as detailed in prior studies (34, 35). For multistep
growth curves, cells were infected at a low multiplicity of infection (MOI
of 0.001) with or without IFN- pretreatment (12 h, 10 IU/ml; PBL In-
terferon Source) or IFN- pretreatment (4 h, 0.4 ng/ml; PBL Interferon
Source). Virus was harvested from supernatants at specific times and
titrated by focus-forming assay on Vero cells.
Statistical analysis. Kaplan-Meier survival curves were analyzed by
the log rank test. A two-tailed Student t test was used to determine statis-
tically significant differences for in vitro experiments. TheMann-Whitney
test was used to analyze differences in viral burden. All data were analyzed
by using Prism software (GraphPad Software).
RESULTS
Ifit2 is required for control of WNV infection in vivo. To deter-
mine whether a deficiency of Ifit2 resulted in increased suscepti-
bility to lethalWNV infection, we infectedwild-type and congenic
Ifit2/mice via a subcutaneous route with 102 PFUofWNV, and
survival was monitored (Fig. 1A). A higher percentage of Ifit2/
mice succumbed to lethal WNV infection than wild-type mice
(92% compared to 38%; P 	 0.001). Moreover, we observed a
significant decrease in the mean time to death (10.0 compared to
12.2 days; P 	 0.01) in Ifit2/ compared to wild-type mice. As
IFIT genes are implicated in the recognition and control of flavi-
viruses, coronaviruses, and poxviruses lacking 2=-O methylation
of the 5= viral RNA cap structures (17, 18, 36), we also tested
whether an absence of Ifit2 affected pathogenicity of WNV-NS5-
E218A. Previous studies established that this WNV mutant virus
lacked 2=-Omethyltransferase activity andwas attenuated inwild-
type mice (26) yet more virulent in Ifit1/mice (17, 18). Unex-
pectedly,WNV-NS5-E218A remained attenuated in Ifit2/ adult
mice, as no illness ormortalitywas observed after subcutaneous or
intracranial challenge (data not shown). Thus, while Ifit2 had a
protective effect against a virulent strain ofWNV in vivo, it was not
required for restricting viruses lacking 2=-O methylation.
Ifit2 restricts WNV replication in different tissues. To begin
to understand how Ifit2 restricts WNV infection in vivo, we mea-
sured viral burdens in serum, peripheral organs (spleen, kidney,
and draining lymph node), and CNS tissues (brain and spinal
cord) at different days after subcutaneous infection.
In the serum and draining lymph nodes, we observed a small
(3- to 140-fold) yet statistically significant (P 	 0.02) increase in
WNV replication in Ifit2/mice, but only at day 4 after infection
(Fig. 1B and C). However, we failed to detect differences in the
kinetics or magnitude of WNV infection in the spleen or kidney
(Fig. 1D and E) compared to that in mice deficient in IFN-I sig-
naling (34, 37). Overall, compared to mice lacking other innate
immune signaling molecules (e.g., Mavs, Irf3, Irf7, or Ifnar) (37–
40), a loss of Ifit2 expression had a limited effect on WNV infec-
tion in peripheral organs.
We next assessed the effects of an absence of Ifit2 on WNV
infection in CNS tissues (Fig. 1F and G). At day 4 after subcuta-
neous infection, we observed higher levels (P
 0.02) of infection
in the brains of Ifit2/mice than in wild-typemice. At day 8 after
infection, there was a trend toward increased viral burden in the
brain and spinal cord of Ifit2/ mice, although this failed to at-
tain statistical significance.
Cho et al.
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Given that a deficiency of Ifit2 resulted in a trend toward in-
creased viral burden in the CNS at day 8 after infection, we hy-
pothesized that Ifit2 might restrict infection in some but not all
regions, which could obscure small differences. To test this, we
infected wild-type and Ifit2/mice and at day 9 harvested tissues
from different regions of the CNS and analyzed their viral burden.
Notably, viral infection in Ifit2/micewas higher in the olfactory
bulb (105.0 versus 103.9 PFU/g;P
 0.004), brain stem (106.4 versus
104.9 PFU/g; P
 0.004), and cerebellum (105.3 versus 104.6 PFU/g;
P 
 0.009) than that in wild-type mice (Fig. 2A, C, and D). In
comparison, no difference in viral burden was observed in the
cerebral cortex or the spinal cord (P 0.1; Fig. 2B and E). Overall,
these data indicate that Ifit2 has a role in restricting WNV infec-
tion in specific regions of the brain.
Cytokine levels in circulation of Ifit2/ mice. Because Ifit2
has been suggested to inhibit STING, a mitochondrial adaptor
protein that recruits TBK1 and IRF-3 to a complex withMAVS to
induce IFN- expression (21), we assessed whether a deficiency of
FIG 1 Survival and viral burden analysis of wild-type and Ifit2/mice. (A) Eight-week-old age-matched wild-type (n
 28) and Ifit2/ (n
 29) mice were
infected via the subcutaneous route with 102 PFUofWNVandmonitored formortality for 21 days. Survival differences were judged by the log rank test andwere
statistically significant (P	 0.0001). (B to G) WNV tissue burden and spread in mice after subcutaneous infection. WNV levels in serum (B), draining lymph
node (C), spleen (D), kidney (E), brain (F), and spinal cord (G) of wild-type and Ifit2/mice were measured by quantitative RT-PCR (qRT-PCR) (B and C) or
by infectious plaque assay (D to G) of samples harvested at the indicated time points. Data are shown asWNV genome equivalents per microgram of 18S rRNA
(r18S) or PFU per gram of tissue for 3 to 15mice per time point. Solid lines represent themedian viral titers, and dotted lines denote the limits of detection of the
respective assays. Asterisks indicate values that are statistically significant (*, P	 0.05; ***, P	 0.0001).
FIG 2 WNV replication in regions of the CNS of Ifit2/mice after subcutaneous infection. Wild-type and Ifit2/mice were infected with 102 PFU of WNV
via the subcutaneous route. Different regions of the brain were harvested at day 9: olfactory bulb (A), cerebral cortex (B), brain stem (C), cerebellum (D), and
spinal cord (E). Tissue homogenates were analyzed for viral burden by plaque assay. Data are shown as PFU per gram of tissue from 11 to 14mice per time point.
Solid lines represent the median viral titers, and dotted lines indicate the limits of detection of the respective assays. Asterisks indicate values that are statistically
significant (**, P	 0.001).
Iﬁt2 Restricts West Nile Virus Infection
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Ifit2 affected IFN-I production. Wild-type and Ifit2/mice were
infected with WNV, and the level of biologically active IFN-I in
serum was monitored in a validated encephalomyocarditis virus
(EMCV) L929 cell bioassay (29). Notably, in Ifit2/ mice we
observed IFN-I activity levels that were moderately higher (2- to
15-fold; P	 0.05) than those in the wild type at every time point
tested (Fig. 3). This may be due to increased viral replication in
cells of Ifit2/mice or to the proposed loss of negative regulatory
effects on cytokine production (41). Because of the elevated IFN-I
levels and prior reports suggesting that Ifit2 might regulate in-
flammatory responses (41), we also measured cytokine levels in
serum from wild-type and Ifit2/ mice at day 2 after infection.
No differences in interleukin 1 (IL-1), IL-6, IL-10, IL-12 (p40
subunit), IFN-, TNF-, CXCL1, and CCL4 cytokines and
chemokines were observed (data not shown).
Effect of Ifit2 on adaptive immune responses toWNV infec-
tion.We next investigated whether an absence of Ifit2 influenced
the development of an effective adaptive immune response during
infection, as prior studies suggest that depressed T and B cell re-
sponses can result in enhanced WNV replication in the CNS (27,
42–44). Initially, we evaluated T cell responses in the spleen.
Equivalent percentages of CD4 and CD8 T cells were isolated
from spleens ofwild-type and Ifit2/mice (Fig. 4A andB).More-
over, we observed no difference in the percentage of WNV-spe-
cific CD8 T cells that expressed IFN-, TNF-, or IFN- and
TNF- (double positive) after ex vivoNS4B peptide restimulation
in wild-type and Ifit2/mice (Fig. 4C to E).
Although peripheral T cell primingwas equivalent, we assessed
whether leukocyte migration into the CNS might be altered in
Ifit2/mice, as infiltrating leukocytes into the brain clearsWNV
infection (43–45). In the brain, at day 8 after infection, we ob-
served similar percentages and numbers of CD8T cells (P 0.6)
(Fig. 5A). Antigen specificity was inferred after intracellular stain-
ing of IFN- or TNF- in brain CD8 T cells that were restimu-
lated with the NS4B peptide. No statistical differences were ob-
served in the percentage or number of antigen-specific IFN-
CD8 or TNF-CD8T cells in the brain (P 0.2) (Fig. 5B and
C). We also observed similar numbers of CD11bhigh CD45high
macrophages (P 
 0.4) and CD11bhigh CD45low microglia (P 
0.7) (Fig. 5D and E).
To assess the effect of Ifit2 on WNV-specific humoral re-
sponses, we analyzed serum from Ifit2/ and wild-type mice for
binding to theWNV E protein. At days 6 and 8 after infection, no
appreciable differences in levels of anti-WNV E protein IgM were
observed between Ifit2/ and wild-type mice (P  0.08) (Fig.
6A). Similar levels of WNV-specific IgG also were detected in
Ifit2/ and wild-type mice at day 8 after infection (P 0.1) (Fig.
6B). Consistent with this, no defect in the levels of neutralizing
antibodies was observed in Ifit2/mice (P 0.3) (Fig. 6C). To-
gether, these results suggest that the virological phenotype ob-
served in Ifit2/mice was not due to major defects in T or B cell
function.
Ifit2 controls WNV replication in subsets of primary cells.
Given the variation in tissue-specific virological phenotypes in
Ifit2/mice, we speculated that theremight be cell-specific func-
tions of Ifit2 in restricting WNV replication. To assess this, we
compared multistep growth kinetics in several different wild-type
and Ifit2/ primary cells, including macrophages, myeloid den-
dritic cells, embryonic fibroblasts (MEFs), cortical neurons, and
cerebellar granule cell neurons after WNV infection at a lowMOI
(0.001 to 0.01). In macrophages, cortical neurons, and MEFs, we
observed no difference in WNV infection between wild-type and
FIG 3 Cytokine levels in serum of wild-type and Ifit2/mice after infection
withWNV.Wild-type and Ifit2/mice were inoculated subcutaneously with
102 PFU ofWNV, and serumwas collected on days 2 to 8 after infection. IFN-I
activity was determined in a bioassay. Solid lines represent the median con-
centrations, and dotted lines indicate the limits of detection of the respective
assays. Asterisks indicate differences that are statistically significant by the
Mann-Whitney test (*, P	 0.05; ***, P	 0.0001).
FIG 4 Peripheral T cell responses afterWNV infection in Ifit2/mice.Wild-
type and Ifit2/mice were inoculated subcutaneously with 102 PFU ofWNV,
and spleens were harvested at day 8 after infection. (A and B) Percentage of
CD3 CD4 (A) or CD3 CD8 (B) cells in the spleen after being gated on
live cells; (C and D) data are shown as the percentage of CD3 CD8 T cells
that expressed intracellular IFN- or TNF- after Db-restricted NS4B peptide
restimulation ex vivo. The differences were not statistically significant, and the
data were pooled from two independent experiments with a total of 7 or 8
mice. (E) Flow cytometry dot plots showing intracellular IFN- and TNF-
staining after NS4B peptide restimulation and gating on CD8 T cells.
Cho et al.
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Ifit2/ cells (Fig. 7A to C). In comparison, small (2- to 3-fold) yet
statistically significant (P 	 0.05) increases in WNV infection
were observed at the 48- and 72-h time points in Ifit2/ cerebel-
lar granule cells and at the 72-h time point in Ifit2/ dendritic
cells (Fig. 7D and E). The antiviral effect of Ifit2 was magnified
when cells were primed with different subtypes of IFN-I. The level
of WNV replication was higher in IFN--pretreated Ifit2/
MEFs (2- to 5-fold; P 	 0.05) and macrophages (20-fold; P 	
0.01) than in wild-type cells (Fig. 7F and G). Similar results were
observed after treatment with another mouse IFN-I, IFN- (also
known as limitin) (Fig. 7H). Overall, our results establish a cell
type-specific effect of Ifit2 on WNV replication, which can be
magnified in the context of an IFN-I response.
Ifit2 has a direct role in restricting WNV replication in the
CNS.Previous studies suggested a direct role of Ifit2 in controlling
virus replication in the CNS (20, 46). Because our survival and
virological experiments through a peripheral route suggested that
Ifit2 contributed to the control ofWNV infection in selected CNS
tissues, we directly introduced virus into the brain after intracra-
nial injection and monitored spread to the contralateral brain re-
gions (olfactory bulb, cerebral cortex, brain stem, spinal cord,
cerebellum) on days 2, 4, and 6 after inoculation (Fig. 8A to E).
FIG 5 Leukocyte accumulation in the CNS of Ifit2/ mice after WNV infection. Wild-type and Ifit2/ mice were infected with 102 PFU of WNV by a
subcutaneous route, and 8 days later brains were harvested and leukocytes were isolated by Percoll gradient centrifugation. (A) Total percentages and numbers
of CD3 CD8 T cells; (B) total percentages and numbers of CD3 CD8 T cells that expressed intracellular IFN- or TNF- after restimulation with a
Db-restricted NS4B peptide; (C) flow cytometry dot plots showing intracellular IFN- and TNF- cells after peptide restimulation and gating on CD8 T cells;
(D) total percentages and numbers of activated microglia (CD11bhigh CD45low) and macrophages (CD11bhigh CD45high). The differences were not statistically
significant, and the data were pooled from two independent experiments with a total of 7 or 8 mice. (E) Flow cytometry dot plots indicating gating strategy for
defining activated microglia and macrophages.
FIG 6 WNV-specific IgM and IgG responses in wild-type and Ifit2/mice. Wild-type and Ifit2/mice were infected with WNV via the subcutaneous route,
and serum was collected at the indicated time points. The development of WNV-specific IgM (A) or IgG (B) was determined by ELISA using purified WNV E
protein. (C) Sera were harvested from animals at the indicated times postinfection and tested for neutralization activity using a focus reduction assay (see
Materials and Methods). Data represent the effective reciprocal dilution of sera that produced 50% neutralization of WNV infection (EC50). Data are from 7 to
11 mice per group. Differences were not statistically significant (P 0.05) as judged by the Mann-Whitney test.
Iﬁt2 Restricts West Nile Virus Infection
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Threshold levels of infection were detected at day 2 after infection
in wild-type and Ifit2/ mice. By day 4, viral titers of Ifit2/
mice were substantially higher in the olfactory bulb (105.0 versus
103.1 PFU/g; P
 0.002), cerebral cortex (106.9 versus 103.5 PFU/g;
P 
 0.0001), brain stem (105.6 versus 102.9 PFU/g; P 	 0.0001),
cerebellum (105.5 versus 102.8 PFU/g; P
 0.0002), and spinal cord
(105.1 versus 102.6 PFU/g; P 	 0.0001) than in wild-type mice.
Nonetheless, by day 6, viral titers of wild-typemice became equiv-
alent to those observed in Ifit2/mice. These results suggest that
the antiviral action of Ifit2 restricts WNV spread in the CNS, es-
pecially during the early stages of virus spread.
DISCUSSION
Subsets of ISGs are responsible for the antiviral effector functions
of IFN-I.While several hundred ISGs have been identified by tran-
scriptional profiling and RNAseq studies (47), relatively few have
been shown directly to inhibit viral infections (48). IFIT genes
encode a family of proteins that are induced after IFN treatment,
viral infection, or pathogen-associatedmolecular pattern (PAMP)
recognition (49, 50). Four family members have been character-
ized in humans (IFIT1 [ISG56], IFIT2 [ISG54], IFIT3 [ISG60],
and IFIT5 [ISG58]), and three members are expressed in mice
(Ifit1 [Isg56], Ifit2 [Isg54], and Ifit3 [Isg49]). We initiated these
pathogenesis studies because preliminary data suggested that Ifit2
had antiviral activity against attenuated WNV strains in cell cul-
ture (17, 19). Indeed, our analysis here shows a key role for Ifit2-
dependent restriction of WNV infection in vivo. Ifit2/ mice
showed enhanced susceptibility to virulent WNV infection, and
this was associated with elevated levels of infection in subsets of
CNS tissues. A direct effect of Ifit2 on neuronal cell infection and
spread in vivo also was suggested, as deficient mice exhibited a
higher viral burden in CNS tissues following intracranial inocula-
tion. Finally, a multistep viral growth analysis of primary cells
confirmed a cell type-specific antiviral function of Ifit2, as Ifit2/
myeloid cells, embryonic fibroblasts, and cerebellar granule cell
neurons but not cortical neurons showed enhanced infectivity.
This phenotype was magnified in the context of priming with
IFN-I, which is consistent with the hypothesis that IFN-induced
Ifit2 expression in some cell types restricts WNV replication.
A previous study also suggested an antiviral function of Ifit2 in
a subset of CNS tissues against VSV in vivo (20). In that report,
Ifit2 inhibitedVSV replication in the cortex, brain stem,midbrain,
and cerebellum after intranasal infection. Analogously, in our
study, Ifit2 limitedWNV infection inmultiple regions of the brain
after intracranial infection. These results suggest that Ifit2 contrib-
utes to protection against viral pathogenesis in the brain, which is
consistent with the observation that Ifit2 is induced in many re-
gions of the brain upon viral infection (51). Nonetheless, in our
subcutaneous infectionmodel, some regions of the CNS (cerebral
cortex and spinal cord) failed to show enhanced infection in
Ifit2/ mice, although this could reflect the time point that was
assessed in these experiments. Moreover, Ifit2/ mice did not
show increased viral infection in visceral organs such as the spleen
and kidney, which could reflect the restricted expression pattern
FIG 7 WNV replication in wild-type and Ifit2/ primaryMEFs, myeloid cells, and neurons. Primary cells from wild-type and Ifit2/mice were infected with
WNV, and viral replication from 6 to 72 h was measured by focus-forming assay. Shown are data from bone marrow-derived macrophages (MOI, 0.01) (A),
cortical neurons (MOI, 0.001) (B), MEFs (MOI, 0.01) (C), cerebellar granule cell neurons (MOI, 0.001) (D), and bone marrow-derived dendritic cells (MOI,
0.001) (E). (F to H) MEFs (F) and bone marrow-derived macrophages (G and H) were pretreated with 10 IU/ml of IFN- (F and G) or 0.4 ng/ml of IFN- (H)
for 4 h and infected with WNV, and viral replication was measured. Asterisks indicate differences that are statistically significant by the Mann-Whitney test (*,
P	 0.05; **, P	 0.001; ***, P	 0.0001).
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of Ifit2 in those tissues (46). The antiviral role of Ifit2 has been
described in the context of other virus infections. Our data show-
ing an antiviral role of Ifit2 are consistent with recent data with
influenza A virus, although the mechanisms of action may differ.
Ifit2 was suggested to inhibit influenza A virus by forming a com-
plex with Ifit1 and Ifit3 to recognize the 5=-ppp moiety on
genomic viral RNA (22). In comparison, Ifit2 expression failed to
show any antiviral effects on alphavirus infection in vitro (52).
The identification of Ifit2 as an ISG that restricts WNV infec-
tion in vivo adds to a small number of studies suggesting that the
deletion of individual ISGs can impactWNV pathogenesis. While
a redundancy of antiviral ISGs against a given virus might pre-
clude phenotypes when a single antiviral ISG is targeted for dele-
tion, recent studies with WNV suggest otherwise. Using geneti-
cally deficient mice, several ISGs, including the PKR (protein
kinase R, also known as Eif2ak2), RNase L, and viperin (Rsad2)
genes, were shown to inhibit WNV in vivo. Activated PKR phos-
phorylates the subunit of eukaryotic translation initiation factor
2 (eIF2-), resulting in a block of protein synthesis (26). RNase L
is an endoribonuclease, and, once activated, it cleaves viral RNA
and mRNA, leading to a decrease in protein synthesis and viral
replication (23). Pkr/  RnaseL/ mice were vulnerable to
subcutaneous WNV infection, with increased mortality and viral
replication. Viperin (Rsad2) is an endoplasmic reticulum (ER)-
associated protein that has inhibitory activity against several vi-
ruses, possibly because it inhibits bulk protein secretion, lipid raft
formation, and virus budding and localizes to ER-derived lipid
droplets, which are required for efficient replication by someRNA
viruses (53). viperin/mice infected with WNV also showed in-
creased lethality and/or enhanced viral replication in CNS tissues
(12).
How does Ifit2 inhibit WNV infection? Although more de-
tailed mechanism-of-action studies are required, Ifit2 has been
proposed to inhibit viral translation through its binding to and
inhibition of subunits of eIF3 (14). eIF3 is amultisubunit complex
that functions during the translation initiation step, including as-
sembly of the eIF2-GTP-Met-tRNA ternary complex, formation
of the 43S preinitiation complex, and mRNA recruitment to the
43S preinitiation complex (54).Mouse Ifit2 and human IFIT2 can
block the formation of the 48S complex by binding to eIF3c, and
human IFIT2 can block eIF3 binding to the ternary complex by
interacting with eIF3e (14). Another IFIT family member, human
IFIT1, has been suggested to inhibit influenza andRift Valley fever
virus replication by binding to the 5=-pppmoiety and sequestering
RNA from replication (22), and this phenotype reportedly re-
quired a complex with IFIT2 and IFIT3. While capped WNV
genomic RNA lacks a 5=-ppp end, the negative-strand intermedi-
atemayhave thismoiety exposed (55). Thus, it is possible that Ifit2
inhibits WNV replication by recognizing a 5=-ppp motif on the
negative-strand RNA in a complex with Ifit1. Against the need for
a complex of Ifit proteins for inhibiting wild-typeWNV infection,
no increased replication of lethality was observed in Ifit1/mice
(18). In comparison, recent studies showed that flavivirus mu-
tants lacking 2=-O methyltransferase activity (e.g., WNV-NS5-
E218A) were attenuated in wild-type mice (26, 56, 57) yet more
virulent in Ifit1/mice (17, 18), suggesting that Ifit1 recognizes
RNA cap structures lacking 2=-O methylation to inhibit viral rep-
lication. Although our prior studies suggested that ectopic expres-
FIG 8 WNV replication in regions of the CNS of Ifit2/mice after intracranial infection. Wild-type and Ifit2/mice were infected with 101 PFU of WNV in
10 l of HBSS supplemented with 1% FBS via the intracranial route. Different regions of the contralateral brain were harvested at the indicated time points:
olfactory bulb (A), cerebral cortex (B), brain stem (C), cerebellum (D), and spinal cord (E). Tissue homogenates were analyzed for viral burden by plaque assay.
Data are shown as PFU per gram of tissue for 7 to 18 mice per time point. Solid lines represent the median viral titers, and dotted lines indicate the limits of
detection of the respective assays. Asterisks indicate values that are statistically significant (**, P	 0.001; ***, P	 0.0001).
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sion of Ifit2 might inhibit such viruses, WNV-NS5-E218A re-
mained attenuated in Ifit2/mice; this demonstrates that Ifit2 is
not absolutely required for inhibition of WNV strains lacking
2=-O methylation.
Our experiments also revealed no appreciable difference in B
and T cell responses between Ifit2/ and wild-type mice during
WNV infection. This suggests that the absence of Ifit2 does not
influence the development of effective adaptive immunity during
viral infection.
In summary, our results show that Ifit2 contributes to the an-
tiviral response against WNV in vivo, as its targeted deletion was
associated with increased lethality and selectively enhanced repli-
cation in specific tissues, without an appreciable negative effect of
the innate or adaptive T cell or antibody responses. Based on the
tissue-specific antiviral effects of Ifit2, we speculate that different
cell types might differentially require Ifit2 to restrict WNV repli-
cation. The importance of Ifit2 as an antiviral molecule in a given
cell typemay reflect the qualitative and quantitative ISG signature
that is induced (10, 58). A more detailed biochemical and cellular
analysis is planned to reveal mechanistically how Ifit2 restricts
infectivity of WNV in different subsets of cells.
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